MAM
CTMX icon

Martingale Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Martingale Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,827
Closed -$131K – 843
2021
Q1 		$131K Buy
+16,827
New +$133K ﹤0.01% 830
2020
Q4 		– Sell
-99,423
Closed -$662K – 914
2020
Q3 		$662K Sell
99,423
-33,193
-25% -$246K 0.01% 744
2020
Q2 		$1.1M Buy
+132,616
New +$1.23M 0.01% 709

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Martingale Asset Management's CTMX Position: Q2 2021 in Review

Martingale Asset Management sold out of CytomX Therapeutics (CTMX) in Q2 2021, closing a stake of 16,827 shares — an estimated $131K sold.

Martingale Asset Management first reported a position in CTMX in Q2 2020 and held it in 3 quarters. The position peaked at $1.1M in Q2 2020. 122 funds tracked by Wall St. Rank hold CTMX as of Q2 2021.

  • Martingale Asset Management reported no remaining CytomX Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Martingale Asset Management sold 16,827 CytomX Therapeutics shares in Q2 2021, an estimated $131K.
  • Martingale Asset Management first reported a position in CytomX Therapeutics in Q2 2020 and held it in 3 quarters.
  • Martingale Asset Management's CytomX Therapeutics position peaked at $1.1M in Q2 2020.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2021.

Based on Martingale Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.